{"denoms":[{"counts":[{"groupId":"BG000","value":"31"}],"units":"Participants"}],"groups":[{"description":"Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels\n\nepoetin alfa: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.","id":"BG000","title":"Epoetin Alfa - 80,000 U sc"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"41","upperLimit":"80","value":"61.9"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"19"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}